parC mutations in fluoroquinolone-resistant Borrelia burgdorferi

Antimicrob Agents Chemother. 2005 Oct;49(10):4354-7. doi: 10.1128/AAC.49.10.4354-4357.2005.

Abstract

We have isolated in vitro fluoroquinolone-resistant mutants of the Lyme disease agent, Borrelia burgdorferi. Mutations in parC, which encodes a subunit of topoisomerase IV, were associated with loss of susceptibility to sparfloxacin, moxifloxacin, and Bay-Y3118, but not ciprofloxacin. This is the first description of fluoroquinolone resistance in the spirochete phylum.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Borrelia burgdorferi / genetics*
  • DNA, Bacterial
  • Drug Resistance, Bacterial / genetics*
  • Fluoroquinolones / pharmacology*
  • Genes, Bacterial
  • Inhibitory Concentration 50
  • Microbial Sensitivity Tests
  • Mutation*
  • Nucleic Acid Amplification Techniques
  • Selection, Genetic
  • Sequence Analysis, DNA

Substances

  • Anti-Infective Agents
  • DNA, Bacterial
  • Fluoroquinolones